Market Place
Sourcing Support
C4 Therapeutics Presents Cemsidomide Phase 1 Data at ASH 2024
08 Dec 2024 //
GLOBENEWSWIRE
C4 Therapeutics` Cemsidomide Phase 1 Data: Promising IKZF1/3 Degrader
08 Dec 2024 //
GLOBENEWSWIRE
C4 Therapeutics Appoints Steve Hoerter To Board Of Directors
20 Nov 2024 //
GLOBENEWSWIRE
C4 Therapeutic Announces 1st Patient Dose in CFT8919 Trial
06 Nov 2024 //
GLOBENEWSWIRE
C4 Therapeutics Presents Cemsidomide Data at ASH Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
C4 Therapeutics Reports Q3 2024 Results & Highlights
31 Oct 2024 //
GLOBENEWSWIRE
C4 Therapeutics Announces Inducement Grant Under Nasdaq Rule
28 Oct 2024 //
#N/A
C4 Therapeutics Appoints Paige Mahaney As Chief Scientific Officer
15 Oct 2024 //
GLOBENEWSWIRE
C4 Therapeutics Announces Presentations At TPD Summit
09 Oct 2024 //
GLOBENEWSWIRE
C4 Therapeutics Announces Inducement Grant Under Nasdaq Rule
30 Sep 2024 //
GLOBENEWSWIRE
C4 Therapeutics Presents CFT1946 Phase 1 Data At ESMO 2024
13 Sep 2024 //
GLOBENEWSWIRE
C4 Therapeutics Delivers Second Development Candidate To Biogen
10 Sep 2024 //
GLOBENEWSWIRE
C4 Therapeutics To Present CFT1946 Phase 1 Data At ESMO Congress
08 Sep 2024 //
GLOBENEWSWIRE
C4 Therapeutics Appoints Stephen Fawell, Ph.D., to Board of Directors
03 Sep 2024 //
GLOBENEWSWIRE
C4 Therapeutics to Participate in Upcoming September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
C4 Therapeutics’ CFT1946 Phase 1 Abstract Changed To Proffered Paper At ESMO
14 Aug 2024 //
GLOBENEWSWIRE
C4 Therapeutics Reports Q2 2024 Results And Business Highlights
01 Aug 2024 //
GLOBENEWSWIRE
C4 Therapeutics To Present CFT1946 Phase 1 Data At ESMO Congress 2024
16 Jul 2024 //
GLOBENEWSWIRE
C4 Therapeutics To Join Virtual UBS Targeted Protein Degradation Day
08 Jul 2024 //
GLOBENEWSWIRE
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
10 Jun 2024 //
GLOBENEWSWIRE
C4 Therapeutics Q1 2024 Results, Business Highlights
08 May 2024 //
GLOBENEWSWIRE
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Apr 2024 //
GLOBENEWSWIRE
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
09 Apr 2024 //
GLOBENEWSWIRE
C4 Therapeutics Presents New Preclinical Data at the AACR
08 Apr 2024 //
GLOBENEWSWIRE
C4 Therapeutics to Present Data on Selective Orally Bioavailable BiDAC Degraders
05 Mar 2024 //
GLOBENEWSWIRE
Merck KGaA paying $16M to join C4`s protein degrader hunt
05 Mar 2024 //
FIERCE BIOTECH
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
C4 Therapeutics cuts staff, restructures to focus on lead programs
10 Jan 2024 //
ENDPTS
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway
09 Jan 2024 //
GLOBENEWSWIRE
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
GLOBENEWSWIRE
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta
04 Jan 2024 //
GLOBENEWSWIRE
Merck & Co. inks deal with C4 on degrader-antibody conjugates
13 Dec 2023 //
GLOBENEWSWIRE
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial
12 Dec 2023 //
GLOBENEWSWIRE
C4 Therapeutics to Host Webcast to Present Dose Escalation Data from CFT7455
28 Nov 2023 //
GLOBENEWSWIRE
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
20 Nov 2023 //
GLOBENEWSWIRE
C4 Therapeutics Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634
11 Oct 2023 //
GLOBENEWSWIRE
C4 Therapeutics Announces Chief Financial Officer Succession
05 Sep 2023 //
GLOBENEWSWIRE
C4 Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Jul 2023 //
GLOBENEWSWIRE
C4 Therapeutics Announces FDA Clearance of Investigational NDA for CFT8919
05 Jul 2023 //
GLOBENEWSWIRE
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
20 Jun 2023 //
GLOBENEWSWIRE
C4 joins Betta`s tank to bring lung cancer drug to greater China
30 May 2023 //
FIERCE BIOTECH
C4 Therapeutics & Betta Pharma Announce Exclusive Licensing Agreement CFT8919
30 May 2023 //
GLOBENEWSWIRE
C4 Therapeutics Reports 1Q 2023 FYR and Recent Business Highlights
04 May 2023 //
GLOBENEWSWIRE
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
19 Apr 2023 //
GLOBENEWSWIRE
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
08 Feb 2023 //
GLOBENEWSWIRE
CCCC stock slips as medical chief departs
03 Feb 2023 //
SEEKINGALPHA
C4 Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946
30 Jan 2023 //
GLOBENEWSWIRE
C4 Announces Priorities to Advance Portfolio of Protein Degradation Medicines
09 Jan 2023 //
GLOBENEWSWIRE
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Versant, NEA launch biotech helmed by ex-CEO of protein degrader C4 Therapeutics
23 Nov 2022 //
ENDPTS
C4 Therapeutics Reports 3Q FYR and Recent Business Highlights
03 Nov 2022 //
GLOBENEWSWIRE
C4 Therapeutics Receives Study May Proceed Letter USFDA Ph1/2 Trial of CFT1946
29 Sep 2022 //
GLOBENEWSWIRE
C4 Therapeutics to Present at Bank of America Securities Precision Oncology
26 Sep 2022 //
GLOBENEWSWIRE
C4 Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
C4 Tx Appoints Experienced Clinical Development Leaders to Board of Directors
02 Aug 2022 //
GLOBENEWSWIRE
Selling US$1.3m worth of C4 Therapeutics stock at high prices
21 Jul 2022 //
SIMPLY WALL
C4 Therapeutics Announces First Patient Dosed in PI/II Trial Evaluating CFT8634
16 May 2022 //
GLOBENEWSWIRE
